Novo Nordisk A/S (CPH:NOVO.B)
Denmark
· Delayed Price · Currency is DKK 635.90
-3.20 (-0.50%)
Mar 4, 2025, 12:21 PM CET
Novo Nordisk Revenue
In the year 2024, Novo Nordisk had annual revenue of 290.40B DKK with 25.03% growth. Novo Nordisk had revenue of 85.68B in the quarter ending December 31, 2024, with 30.09% growth.
Revenue
290.40B
Revenue Growth
+25.03%
P/S Ratio
9.80
Revenue / Employee
3.78M
Employees
77,349
Market Cap
2,837.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
| Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
| Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
| Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
| Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coloplast | 27.45B |
| Genmab | 21.53B |
| Demant | 22.42B |
| Zealand Pharma | 62.69M |
| H. Lundbeck | 22.00B |
| Ambu A/S | 5.65B |
| ALK-Abelló | 5.54B |
| GN Store Nord | 17.99B |
Novo Nordisk News
- 4 days ago - March 25, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO - PRNewsWire
- 4 days ago - Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights – NVO - Accesswire
- 4 days ago - INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Lawsuit Against Novo Nordisk A/S – NVO - Accesswire
- 4 days ago - Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline – NVO - Accesswire
- 4 days ago - Novo Nordisk (NVO) Faces Securities Class Action After Weight Loss Therapy Trial Data Disappoints, Analyst Questions Trial's Design – Hagens Berman - GlobeNewsWire
- 4 days ago - Shareholders of Novo Nordisk A/S Should Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO - Accesswire
- 4 days ago - NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewsWire
- 4 days ago - Novo Nordisk A/S Investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewsWire